Compare SACH & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | VNRX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6M | 40.8M |
| IPO Year | 2017 | N/A |
| Metric | SACH | VNRX |
|---|---|---|
| Price | $1.05 | $0.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.00 | ★ $3.17 |
| AVG Volume (30 Days) | 155.8K | ★ 2.5M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 19.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,906,000.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | $1.73 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $0.80 | $0.27 |
| 52 Week High | $1.48 | $0.94 |
| Indicator | SACH | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 37.99 |
| Support Level | $1.00 | $0.27 |
| Resistance Level | $1.08 | $0.33 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 75.00 | 38.24 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.